Company & Sponsor Intelligence
Merck Sharp & Dohme LLC
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials60
Recruiting17
Completed40
Countries2
Therapeutic footprint
adhdalzheimersdepressionparkinsonsschizophrenia
Indexed studies
NCT02460198Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)
parkinsons · PHASE2
parkinsons · PHASE2
NCT00475735A Study to Test the Safety and Efficacy of MK0249 in Patients With ADHD (0249-018)(COMPLETED)
adhd · PHASE2
adhd · PHASE2
NCT06041802A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)
parkinsons · JapanPHASE2
parkinsons · JapanPHASE2
NCT06504394A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)
parkinsons · United StatesPHASE2
parkinsons · United StatesPHASE2
NCT01905657Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)
parkinsons · PHASE2, PHASE3
parkinsons · PHASE2, PHASE3
NCT03374254Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651)
parkinsons · United StatesPHASE1
parkinsons · United StatesPHASE1
NCT04725188Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)
parkinsons · United StatesPHASE2
parkinsons · United StatesPHASE2
NCT00074529Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)
alzheimers · PHASE2
alzheimers · PHASE2
NCT00042029Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)
depression · PHASE3
depression · PHASE3
NCT02702401Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240)
parkinsons · PHASE3
parkinsons · PHASE3
NCT04220866Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)
parkinsons · United StatesPHASE2
parkinsons · United StatesPHASE2
NCT05173987Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
parkinsons · United StatesPHASE3
parkinsons · United StatesPHASE3
Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →